Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2013

01-12-2013 | Meeting Report

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012

Authors: Michele Maio, Hugues Jean Marie Nicolay, Paolo Antonio Ascierto, Filippo Belardelli, Roberto Camerini, Mario Paolo Colombo, Paola Queirolo, Ruggero Ridolfi, Vincenzo Russo, Giulia Parisi, Ornella Cutaia, Ester Fonsatti, Giorgio Parmiani

Published in: Cancer Immunology, Immunotherapy | Issue 12/2013

Login to get access

Excerpt

NIBIT (acronym for the Network Italiano per la Bioterapia dei Tumori-Italian Network for Tumor Biotherapy) is a non-profit association created in 2004 to promote and foster scientific interactions among Italian and international professionals working in the field of cancer immunotherapy. …
Metadata
Title
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012
Authors
Michele Maio
Hugues Jean Marie Nicolay
Paolo Antonio Ascierto
Filippo Belardelli
Roberto Camerini
Mario Paolo Colombo
Paola Queirolo
Ruggero Ridolfi
Vincenzo Russo
Giulia Parisi
Ornella Cutaia
Ester Fonsatti
Giorgio Parmiani
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 12/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-013-1496-5

Other articles of this Issue 12/2013

Cancer Immunology, Immunotherapy 12/2013 Go to the issue

Original Article

Expansion of CD11b+Ly6G+Ly6Cint cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions

Original Article

CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy

Original Article

Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy

Original Article

Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer

Review

Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma

Original Article

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits